Biotech News2seventy bio Secure $170 Million Extending Cash Runway Into 2025 BioTech Health XMarch 16, 2022 2seventy bio (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced that it has agreed to sell… 1 Shares 0 1 0 0 0 0 0
Biotech NewsInhibikase Therapeutics To Present Phase 1/1b Trial Results at AD/PD Alzheimer’s & Parkinson’s Diseases Conference BioTech Health XMarch 8, 2022 Clinical-stage pharmaceutical company Inhibikase Therapeutics, Inc. (Nasdaq: IKT) recently announced that President and CEO Dr. Milton Werner, Ph.D. will be… 1 Shares 0 1 0 0 0 0 0